Investment Rating - The report maintains an "Accumulate" investment rating for the company [3]. Core Views - The company is a leading player in the domestic ophthalmic medical device industry, focusing on innovation, particularly in intraocular lenses and orthokeratology lenses. The business is expected to gradually recover from the impact of centralized procurement, with the launch of the dual-focus intraocular lens contributing to revenue growth [1][6]. - The company has received special approval from the National Medical Products Administration for its refractive intraocular lens, which is anticipated to facilitate domestic substitution and enhance performance [1][6]. - Revenue projections for the company are optimistic, with expected revenues of 1.734 billion yuan in 2025, representing a 23% year-on-year growth, and net profit expected to reach 465 million yuan, also reflecting a 20% increase [2][6]. Financial Data and Valuation - The company’s total revenue is projected to grow from 951 million yuan in 2023 to 2.56 billion yuan in 2027, with year-on-year growth rates of 64%, 48%, 23%, 22%, and 21% respectively [2][8]. - Operating profit is expected to increase from 327 million yuan in 2023 to 750 million yuan in 2027, with growth rates of 26%, 32%, 20%, 21%, and 19% [2][8]. - The earnings per share (EPS) is projected to rise from 1.57 yuan in 2023 to 3.49 yuan in 2027, with a corresponding decrease in the price-to-earnings (PE) ratio from 49.5 to 22.3 over the same period [2][8]. Market Performance - The current stock price is 77.91 yuan, with a total market capitalization of 15 billion yuan [3]. - The company has experienced a decline in stock performance, with absolute performance down by 25% over the past month and six months, and down 11% over the past year [5]. Shareholder Information - The major shareholder is Xie Jiangbing, holding a 12.68% stake in the company [3].

周大生 002867.SZ 公司研究 | 年报点评 | 金价压制终端需求，高分红政策延续 | | --- | 核心观点 盈利预测与投资建议 ⚫ 根据年报，我们调整盈利预测并引入 2027 年的盈利预测，预计 2025-2027 年每股收 益分别为 0.96、1.14 和 1.3 元（原 25-26 年为 1.16 和 1.33 元），参考可比公司，给 予 2025 年 17 倍 PE 估值，对应目标价 16.32 元，维持"增持"评级 风险提示：行业竞争加剧、终端消费需求减弱，金价波动影响终端消费等 公司主要财务信息 | | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入(百万元) | 16,290 | 13,891 | 14,054 | 15,056 | 16,521 | | 同比增长 (%) | 46.5% | -14.7% | 1.2% | 7.1% | 9.7% | | 营业利润(百万元) | 1,695 | 1,283 | 1,326 | 1,605 | 1,825 | | 同比 ...

证 券 研 究 报 告 万华化学（600309）2024 年报及 2025 年一季报点评 强推（维持） 盈利底部静待复苏，长期看好 MDI 竞争优势 提供超额利润 事件： | 目标价：69.3 | 元 | | --- | --- | | 当前价：58.29 | 元 | ❖ 公司发布 2024 年报暨 2025 年一季报：1）2024FY 实现营收 1820.69 亿元，同 比+3.83%；实现归母净利润 130.33 亿元，同比-22.49%；实现扣非归母净利润 133.59 亿元，同比-18.74%。其中单 2024 年 Q4 实现收入 344.65 亿元，同比/ 环比分别-19.49%/-31.80%；实现归母净利润 19.40 亿元，同比/环比分别- 52.83%/-33.55%；实现扣非归母净利润 24.31 亿元，同比/环比分别-39.39%/- 14.07%；2）2025 年 Q1 实现收入 430.68 亿元，同比/环比分别-6.70%/+24.96%； 实现归母净利润 30.82 亿元，同比/环比分别-25.87%/+58.89%；实现扣非归母 净利润 30.40 亿元，同比/环比分别-26. ...

公司报告 | 首次覆盖报告 物产中大（600704） 证券研究报告 制造业务高增长，估值有望修复 投资+并购，制造业务高增长 物产中大的制造业务收入和毛利润高增长，2016-2024 年年化增速都达 到 26%，其中线缆、轮胎等业务高增长。一方面，"大贸易小制造"，采购、 营销、资金等赋能带动内生增长，2021-24 年制造业务累计投资超过 60 亿元；另一方面，产业链横向和纵向并购，加速制造业务增长，2021-25 年累计并购金额超过 110 亿元。物产中大开展并购，具有天时、地利、人 和：证监会支持，资金成本低廉，国内制造业庞大、分散，物产中大产业 经验丰富、贸易赋能制造。物产中大有望加大产业链上下游及战略新兴产 业投资并购力度，寻求第二增长曲线。 价格趋稳，供应链盈利或企稳 物产中大供应链业务的市场份额从 2014 年的 0.5%上升到 2024 年的 1.3%，钢材、化工产品等核心品类销量持续增长，带动收入和利润趋势性 增长，未来或将延续。但是 2022-24 年商品价格下跌，导致物产中大供 应链业务毛利润下降 30%、利润总额下降 35%。长期看，商品价格呈上 涨趋势，助推物产中大供应链业务盈利增长 ...

公司报告 | 公司点评 继峰股份（603997） 证券研究报告 2025 年乘用车座椅业务盈利能力有望大幅提升。2024 年度乘用车座椅业 务首次实现年度盈亏平衡。2025 年度预计将有 8 个项目进入量产阶段， 乘用车座椅业务营业收入有望大幅攀升。目前仍有多个工厂尚未量产或产 能利用率较低，随着规模效应的产生，乘用车座椅业务盈利能力有望随之 提升。 格拉默整合持续推进，25Q1 已成功扭亏 2024 年公司多措并举优化格拉默经营效率：1）对格拉默人工成本进行优 化，：一是实施裁员计划；二是将工作岗位从高成本地区（如德国）的工作 岗位逐步向低成本国家转移。2）将持有的 TMD LLC 的 100%股权转让予 APC LLC。3）联合采购、产业布局整合、改革考核激励制度等。 格拉默整合已初见成效，2025 年有望随着降本增效措施持续推进，业绩继 续好转。2025Q1 格拉默实现净利润 0.097 亿欧元，实现扭亏。公司将持续 推进格拉默降本工作，进一步加强对格拉默海外业务管控。从中高层管理 人员的任命和考核，到采购成本管控，运营成本管控，产能布局优化等方 面，更全、更细、更深入地去落实和管控。我们认为格拉默业绩 ...

公司报告 | 年报点评报告 24 年全年毛利率/净利率分别为 44.95%/24.17%，同比-1.59/-2.53pct。全年 销售/管理/研发/财务费用率分别为 7.3%/5.27%/6.78%/-1.32%。其中全年完 成股权激励目标，确认股份支付费用达 2339 万元。 24Q4：实现营收 5.25 亿元，同比+39.82%，环比+17.05%；实现归母净利 润 1.04 亿元 ，同 比+21.54% ，环 比-4.97% 。毛 利率/ 净利 率 分别为 41.34%/21.24%，同比-1.82/-1.44pct，环比-6.23/-4.05pct。 25Q1：实现营收 4.78 亿元，同比+29.79%，环比-8.98%；实现归母净利润 1.08 亿元，同比+25.2%，环比+3.78%。毛利率/净利率分别为 42.84%/23.56%， 同比-2.79pct/-0.82pct，环比+1.5pct/+2.32pct。 全年数码喷印设备/墨水/自动化缝纫设备/数字印刷设备营收分别达 9.1/5.2/1.5/1.4 亿元，同比+47.84%/26.15%/37.67%/114.66%；毛利率分别为 43 ...

Investment Rating - The report maintains a "Recommendation" rating for the company, indicating an expectation to outperform the benchmark index by 10%-20% over the next six months [2][8]. Core Insights - The company's Q1 2025 revenue was 2.325 billion yuan, a year-on-year decrease of 20.48%. However, the net loss attributable to shareholders narrowed to 152 million yuan, a 29.82% improvement year-on-year. The adjusted net loss was 146 million yuan, reflecting a 20.5% reduction compared to the previous year [2][8]. - The company optimized its shipment structure, increasing the sales proportion of high-margin products, which led to an overall improvement in gross margin despite the revenue decline. Cost control measures also contributed to a decrease in management expense ratio by 0.23 percentage points and a reduction in financial expense ratio by 2.22 percentage points due to foreign exchange gains [2][8]. - The company is focusing on the development and sales of power battery systems and energy storage products, enhancing its international market penetration through strategic partnerships, particularly with Farasis Energy [2][8]. - A significant change in control occurred on April 15, with the completion of a share transfer agreement, marking an important adjustment in the company's ownership structure and governance [2][8]. - The company faces competitive challenges in the power battery market, leading to adjustments in profit forecasts for 2025-2027, with expected net profits of -274 million yuan, 7 million yuan, and 40 million yuan respectively [2][8]. Financial Summary - For 2025, the total revenue is projected at 10.746 billion yuan, with a year-on-year decline of 8%. The net profit is expected to be -274 million yuan, showing a 17.5% improvement from the previous year [4][9]. - The company’s total assets are estimated to reach 29.850 billion yuan by 2025, with a debt-to-asset ratio of 67.7% [9]. - The earnings per share (EPS) is projected to be -0.22 yuan for 2025, with a significant increase in profitability expected in subsequent years [4][9].

宜昌人福延续稳健，治理优化可期 ——人福医药 2024&25Q1 业绩点评 投资要点 ❑ 我们看好公司在麻醉镇痛领域的领先地位及持续性，核心子公司宜昌人福业绩 稳健增长，新品获批上市，研发管线持续丰富为中长期增长奠定基础；招商局 集团的入主有望为公司发展注入新动力，优化治理并带来产业协同效应。 ❑ 财务表现：2025Q1 利润端显著改善 2024 年公司实现营业收入 254.35 亿元，同比增长 3.71%；实现归母净利润 13.30 亿元，同比下降 37.70%；实现扣非归母净利润 11.39 亿元，同比下降 37.50%。 利润下滑主要原因包括：1）公司营销体系建设、工程项目及物业资产转固、汇 率变动等导致销售、管理、财务三项费用合计同比增加 4.41 亿元；2）计提信用 减值损失 2.83 亿元；3）计提资产减值损失 3.94 亿元，其中对北京巴瑞医疗的商 誉减值计提 2.02 亿元。 2025Q1 公司实现营业收入 61.37 亿元，同比下降 3.61%；实现归母净利润 5.4 亿 元，同比增长 11.09%；实现扣非归母净利润 5.31 亿元，同比增长 14.35%，利润 端改善显著。 证券研究报告 ...

Investment Rating - The report maintains a "Buy" rating for the company, with an expected relative return of over 20% within the next six months [6][17]. Core Views - The company achieved a revenue of 7.799 billion yuan in 2024, representing a year-on-year increase of 23.56%, while the net profit attributable to the parent company was 1.629 billion yuan, a decrease of 12.77% year-on-year [1][2]. - The company is actively expanding its overseas market presence, having sold products to over 100 countries and regions globally, and has established local teams through equity cooperation and subsidiary formation [4]. - The company has received the lowest tax rate in the industry from the EU's anti-dumping investigation, with a rate of 20.6%, compared to 41.7%-66.7% for other Chinese brands [4]. Financial Performance Summary - In Q1 2025, the company reported a revenue of 1.898 billion yuan, a year-on-year increase of 30.72% and a quarter-on-quarter increase of 13.98%. The net profit attributable to the parent company was 429 million yuan, up 41.83% year-on-year and 154.59% quarter-on-quarter [3]. - The gross margin for 2024 was 35.04%, and the net margin was 20.89%, reflecting a decrease of 3.45 and 8.69 percentage points year-on-year, respectively [2]. - The company forecasts net profits of 2.134 billion yuan, 2.531 billion yuan, and 2.875 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 31%, 19%, and 14% [4]. Revenue Breakdown - For the year, the company generated revenue from various products: 3.444 billion yuan from scissor lifts, 2.956 billion yuan from boom lifts, and 772 million yuan from mast lifts, with year-on-year growth rates of 14.41%, 20.84%, and 53.14%, respectively [3]. - Revenue from domestic and international markets was 1.649 billion yuan and 5.523 billion yuan, respectively, with year-on-year changes of -22.23% and +43.83% [3]. Cost and Expense Analysis - The company's expense ratios for sales, management, R&D, and financial costs were 3.26%, 2.88%, 3.28%, and -1.18%, respectively, with year-on-year changes of -0.42%, +0.64%, -0.21%, and +2.7 percentage points [2].

丨证券研究报告丨 公司研究丨点评报告丨东华测试（300354.SZ） [Table_Title] 东华测试：年报业绩实现较快提升，多条业务线 发力增长 报告要点 [Table_Summary] 公司发布年报及一季报，2024 年业绩实现较快提升，主要受益公司多个产品销量、收入维持增 长。25Q1 公司营收和业绩维持平稳增长，显示经营稳健性。公司产品毛利率持续改善，各细 分业务毛利率均有不同程度优化。净利率优化主要受益于毛利率增长，同时期间费用率表现一 定改善。公司继续推动力学产品国产替代，打造高端科研仪器设备平台化产品体系。公司高端 科研仪器设备在国内卡位优势明显，拓品类拓应用有望打开公司成长空间。 分析师及联系人 [Table_Author] 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 赵智勇 倪蕤 刘晓舟 SAC：S0490517110001 SAC：S0490520030003 SAC：S0490524030001 SFC：BRP550 东华测试（300354.SZ） cjzqdt11111 [Table_Title 东华测试：年报业绩实现较快提升，多 ...